[HTML][HTML] Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial
D Ibrahim, L Dulipsingh, L Zapatka, R Eadie… - Infectious diseases and …, 2020 - Springer
Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
D Ibrahim, L Dulipsingh, L Zapatka… - Infectious diseases …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was …
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was …
Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial.
D Ibrahim, L Dulipsingh, L Zapatka, R Eadie, R Crowell… - 2020 - cabidigitallibrary.org
Abstract Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.
D Ibrahim, L Dulipsingh, L Zapatka… - … Diseases & Therapy, 2020 - search.ebscohost.com
Abstract Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …
[HTML][HTML] Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
D Ibrahim, L Dulipsingh, L Zapatka, R Eadie, R Crowell… - 2020 - europepmc.org
We conducted a prospective single-arm open-label phase II clinical trial assessing the safety
and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent …
and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent …
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
D Ibrahim, L Dulipsingh, L Zapatka, R Eadie, R Crowell… - medRxiv, 2020 - medrxiv.org
We conducted a prospective single-arm open-label phase II clinical trial assessing the safety
and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent …
and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent …
[PDF][PDF] Study Title
D Ibrahim - scholar.archive.org
Abstract 24 We conducted a prospective single-arm open-label phase II clinical trial
assessing the 25 safety and efficacy of convalescent plasma in hospitalized COVID-19 …
assessing the 25 safety and efficacy of convalescent plasma in hospitalized COVID-19 …
Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
D Ibrahim, L Dulipsingh, L Zapatka… - Infectious Diseases …, 2020 - search.proquest.com
Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1: 320)
obtained from recovered donors was administered to adult patients with either severe or …
obtained from recovered donors was administered to adult patients with either severe or …
[PDF][PDF] Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseII Clinical Trial
D Ibrahim, LDL Zapatka, RERCK Williams… - scienceopen.com
ABSTRACT Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory
syndrome caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). This …
syndrome caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). This …
[HTML][HTML] Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
D Ibrahim, L Dulipsingh, L Zapatka… - Infectious Diseases …, 2020 - ncbi.nlm.nih.gov
Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1: 320)
obtained from recovered donors was administered to adult patients with either severe or …
obtained from recovered donors was administered to adult patients with either severe or …